Navigation Links
Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
Date:2/6/2012

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 14th Annual BIO CEO & Investor Conference in New York.   

The live presentation takes place on Monday, February 13 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences Reports Third Quarter 2011 Results
2. Neurocrine Biosciences Reports Second Quarter 2011 Results
3. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
4. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
5. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
6. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
8. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
9. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
10. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2019)... Kingdom (PRWEB) , ... December 03, 2019 , ... ... recombinant antibody products and services, today announced a partnership with the Recombinant Antibody ... University of Toronto, and UC San Francisco (UCSF) with a common goal to ...
(Date:12/4/2019)... ... December 04, 2019 , ... Improved Pharma’s analytical methods provide ... Additionally, their PDF Synchrotron methods provide a way to determine the structure of ... regulatory and patent applications.  , The latest developments were recently shared at the ...
(Date:11/27/2019)... ... November 25, 2019 , ... Silony Medical, a ... robotic-assisted and navigated surgery in the UK. The procedure was performed in the ... Dr. Syed Aftab and Dr. Alexander Montgomery. The surgery, which took place on ...
(Date:11/20/2019)... NEWTOWN, Conn. (PRWEB) , ... November 20, 2019 ... ... is projecting worldwide production of about 8,500 microturbine electrical power generation units from ... is a significant increase over 2017's projection of 3,821 units worth $569 million. ...
Breaking Biology Technology:
(Date:11/12/2019)... ... November 12, 2019 , ... In’Tech Medical SAS ( ... the creation of a Global Regulatory Affairs Department, to support Medical Device companies ... the regulatory element to any Medtech organization is more important than Research & ...
(Date:11/12/2019)... BEND, Ore. (PRWEB) , ... November 12, 2019 ... ... is launching Cross-Channel Spend Optimizer that improves digital advertising performance up to 25% ... Smart Digital Advertising, Cross-Channel Spend Optimizer uses advanced multi-touch attribution (MTA) to predict ...
(Date:11/12/2019)... ... 2019 , ... Atlantic Ultraviolet Corporation (AUV), the premier manufacturer ... their patented automatic and manual wipers the #1 best feature of the ... task required of an ultraviolet water purifier is quartz sleeve cleaning. A fouled ...
Breaking Biology News(10 mins):